Iovance Biotherapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Iovance Biotherapeutics has a total shareholder equity of $584.6M and total debt of $1,000.0K, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are $780.4M and $195.7M respectively.
Key information
0.2%
Debt to equity ratio
US$1.00m
Debt
Interest coverage ratio | n/a |
Cash | US$279.87m |
Equity | US$584.61m |
Total liabilities | US$195.74m |
Total assets | US$780.35m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0JDK's short term assets ($307.8M) exceed its short term liabilities ($110.3M).
Long Term Liabilities: 0JDK's short term assets ($307.8M) exceed its long term liabilities ($85.4M).
Debt to Equity History and Analysis
Debt Level: 0JDK has more cash than its total debt.
Reducing Debt: 0JDK's debt to equity ratio has increased from 0% to 0.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0JDK has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 0JDK has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 23.8% each year.